ALB and chronic kidney disease: gov identifier: NCT03594110), empagliflozin was used in a broad range of patients with CKD who are were at increased risk of progression to end-stage renal disease.68 By the end of the trial, patients in the empagliflozin group had lower risk for kidney disease progression compared with those receiving placebo (HR, 0.72; 95% CI 0.64–0.82; p<0.001).72 This was the first trial that included patients with an eGFR of less than 30 ml/min/1.73 m2 and an albumin–creatinine ratio (ACR) of <300 mg/g.